Data / Drug companies / Northwind Health Company, LLC
Northwind Health Company, LLC: 468 products in the FDA NDC directory, labeler code 51655
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Northwind Health Company, LLC (labeler code 51655) lists 468 products in the FDA National Drug Code Directory, covering 136 finished drugs by generic name. By type: 461 prescription drugs, 7 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on December 30, 2025.
The request: Watch Northwind Health Company, LLC (FDA labeler code 51655): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 51655
- Products in commercial distribution
- 468
- Packages
- 898
- Finished drugs by generic name
- 136
- Prescription products
- 461
- Over the counter products
- 7
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 5
- Earliest marketing start
- March 11, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 440 | 94% |
| New drug applications (NDA) | 12 | 2.6% |
| Authorized generics (NDA) | 11 | 2.4% |
| Other unapproved drugs | 5 | 1.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 461 | 98.5% |
| Over the counter drugs | 7 | 1.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 236 | 50.4% |
| Tablet, film coated | 126 | 26.9% |
| Capsule | 48 | 10.3% |
| Tablet, extended release | 22 | 4.7% |
| Tablet, film coated, extended release | 12 | 2.6% |
| Tablet, coated | 8 | 1.7% |
| Tablet, delayed release | 6 | 1.3% |
| Capsule, delayed release | 4 | 0.9% |
| Tablet, orally disintegrating | 4 | 0.9% |
| Capsule, extended release | 2 | 0.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Metformin hydrochloride extended release | 51655-555 | Tablet, extended release | Generic drugs (ANDA) | December 30, 2025 |
| Medroxyprogesterone Acetate | 51655-520 | Tablet | Generic drugs (ANDA) | December 27, 2023 |
| Amlodipine besylate | 51655-044 | Tablet | Generic drugs (ANDA) | November 30, 2023 |
| Metformin hydrochloride | 51655-559 | Tablet, extended release | Generic drugs (ANDA) | October 11, 2023 |
| Promethazine Hydrochloride | 51655-758 | Tablet | Generic drugs (ANDA) | October 4, 2023 |
| Amlodipine besylate | 51655-869 | Tablet | Generic drugs (ANDA) | August 25, 2023 |
| Valsartan | 51655-653 | Tablet | Generic drugs (ANDA) | August 15, 2023 |
| Fenofibrate | 51655-866 | Tablet | Generic drugs (ANDA) | July 10, 2023 |
| Metformin Hydrochloride | 51655-644 | Tablet, film coated | Generic drugs (ANDA) | July 6, 2023 |
| Alfuzosin hydrochloride | 51655-967 | Tablet, extended release | Generic drugs (ANDA) | June 29, 2023 |
| Glipizide | 51655-966 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 27, 2023 |
| Acyclovir | 51655-965 | Capsule | Generic drugs (ANDA) | June 27, 2023 |
| Terazosin | 51655-915 | Capsule | Generic drugs (ANDA) | June 26, 2023 |
| Sotalol Hydrochloride | 51655-450 | Tablet | Generic drugs (ANDA) | June 14, 2023 |
| Dicyclomine hydrochloride | 51655-548 | Tablet | Generic drugs (ANDA) | June 12, 2023 |
| Allopurinol | 51655-546 | Tablet | Generic drugs (ANDA) | June 8, 2023 |
| Progesterone | 51655-542 | Capsule | Generic drugs (ANDA) | May 25, 2023 |
| Prednisone | 51655-541 | Tablet | Generic drugs (ANDA) | May 19, 2023 |
| Benazepril Hydrochloride | 51655-388 | Tablet, film coated | Generic drugs (ANDA) | May 19, 2023 |
| Levetiracetam | 51655-325 | Tablet, film coated | Generic drugs (ANDA) | May 19, 2023 |
| Rosuvastatin calcium | 51655-458 | Tablet, film coated | Generic drugs (ANDA) | May 9, 2023 |
| Prednisone | 51655-359 | Tablet | Generic drugs (ANDA) | May 9, 2023 |
| Naproxen | 51655-457 | Tablet | Generic drugs (ANDA) | May 4, 2023 |
| Venlafaxine | 51655-323 | Tablet | Generic drugs (ANDA) | May 2, 2023 |
| Ramipril | 51655-904 | Capsule | Generic drugs (ANDA) | April 27, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.